Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tomoki Naoe

Showing results (181-190 of 288) with videos related to

Pageof 29
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|November 14, 2008
BCR-ABL-transformed GMP as myeloid leukemic stem cellsYosuke Minami, Scott A Stuart, Tomokatsu Ikawa, et al.
Cancer Science|October 24, 2013
De novo diffuse large B-cell lymphoma with a CD20 immunohistochemistry-positive and flow cytometry-negative phenotype: molecular mechanisms and correlation with rituximab sensitivityTakashi Tokunaga, Akihiro Tomita, Keiki Sugimoto, et al.
British Journal of Haematology|April 25, 2009
CMC-544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells: analyses in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymphomaAkihiro Takeshita, Kaori Shinjo, Nozomi Yamakage, et al.
Leukemia Research|January 7, 2018
Distinct gene alterations with a high percentage of myeloperoxidase-positive leukemic blasts in de novo acute myeloid leukemiaRena Kamijo, Hidehiro Itonaga, Rika Kihara, et al.
Blood Advances|February 2, 2019
Randomized study of imatinib for chronic myeloid leukemia: comparing standard dose escalation with aggressive escalationKoichi Miyamura, Kazunori Ohnishi, Shigeki Ohtake, et al.
The New England Journal of Medicine|June 22, 2012
Thrombosis from a prothrombin mutation conveying antithrombin resistanceYuhri Miyawaki, Atsuo Suzuki, Junko Fujita, et al.
Cancer Science|December 21, 2021
Phase 1/2 study evaluating the safety and efficacy of DSP-7888 dosing emulsion in myelodysplastic syndromesYasunori Ueda, Kensuke Usuki, Jiro Fujita, et al.
Cancer Science|July 9, 2010
Trough plasma concentration of imatinib reflects BCR-ABL kinase inhibitory activity and clinical response in chronic-phase chronic myeloid leukemia: a report from the BINGO studyYuichi Ishikawa, Hitoshi Kiyoi, Keisuke Watanabe, et al.
Cancer Science|May 19, 2011
Phase I trial of gemtuzumab ozogamicin in intensive combination chemotherapy for relapsed or refractory adult acute myeloid leukemia (AML): Japan Adult Leukemia Study Group (JALSG)-AML206 studyNoriko Usui, Akihiro Takeshita, Chiaki Nakaseko, et al.
Cancer Science|April 28, 2015
Phase I study of OPB-51602, an oral inhibitor of signal transducer and activator of transcription 3, in patients with relapsed/refractory hematological malignanciesMichinori Ogura, Toshiki Uchida, Yasuhito Terui, et al.
Pageof 29

Showing results (181-190 of 288) with videos related to

Sort By:
Pageof 29
Proceedings of the National Academy of Sciences of the United States of America|November 14, 2008
BCR-ABL-transformed GMP as myeloid leukemic stem cellsYosuke Minami, Scott A Stuart, Tomokatsu Ikawa, et al.
Cancer Science|October 24, 2013
De novo diffuse large B-cell lymphoma with a CD20 immunohistochemistry-positive and flow cytometry-negative phenotype: molecular mechanisms and correlation with rituximab sensitivityTakashi Tokunaga, Akihiro Tomita, Keiki Sugimoto, et al.
British Journal of Haematology|April 25, 2009
CMC-544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells: analyses in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymphomaAkihiro Takeshita, Kaori Shinjo, Nozomi Yamakage, et al.
Leukemia Research|January 7, 2018
Distinct gene alterations with a high percentage of myeloperoxidase-positive leukemic blasts in de novo acute myeloid leukemiaRena Kamijo, Hidehiro Itonaga, Rika Kihara, et al.
Blood Advances|February 2, 2019
Randomized study of imatinib for chronic myeloid leukemia: comparing standard dose escalation with aggressive escalationKoichi Miyamura, Kazunori Ohnishi, Shigeki Ohtake, et al.
The New England Journal of Medicine|June 22, 2012
Thrombosis from a prothrombin mutation conveying antithrombin resistanceYuhri Miyawaki, Atsuo Suzuki, Junko Fujita, et al.
Cancer Science|December 21, 2021
Phase 1/2 study evaluating the safety and efficacy of DSP-7888 dosing emulsion in myelodysplastic syndromesYasunori Ueda, Kensuke Usuki, Jiro Fujita, et al.
Cancer Science|July 9, 2010
Trough plasma concentration of imatinib reflects BCR-ABL kinase inhibitory activity and clinical response in chronic-phase chronic myeloid leukemia: a report from the BINGO studyYuichi Ishikawa, Hitoshi Kiyoi, Keisuke Watanabe, et al.
Cancer Science|May 19, 2011
Phase I trial of gemtuzumab ozogamicin in intensive combination chemotherapy for relapsed or refractory adult acute myeloid leukemia (AML): Japan Adult Leukemia Study Group (JALSG)-AML206 studyNoriko Usui, Akihiro Takeshita, Chiaki Nakaseko, et al.
Cancer Science|April 28, 2015
Phase I study of OPB-51602, an oral inhibitor of signal transducer and activator of transcription 3, in patients with relapsed/refractory hematological malignanciesMichinori Ogura, Toshiki Uchida, Yasuhito Terui, et al.
Pageof 29